CTMXCytomX Therapeutics, Inc.
$2.46-26% 1Y
$2.46
$2.4652 weeks$6.75
Latest close: a new 52-week lowOct 8, 2026what changed →
CTMX in its own filings
CTMX's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
212
Events found in the filings · across 796 filings · the record starts in 2015
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 19, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Restatement admitted (non-reliance)historical
- 2023-02-24
- Change in certifying accountanthistorical
- 2017-07-17
- Delisting notice / listing-rule failurepast_3y
- 2025-02-26
- SEC comment-letter activity22 occurrences
- 2025-08-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026CytomX Therapeutics Announces Q2 2026 Financial Results and Provides.Earnings release · press release
- Jul 27, 2026On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director, with an initial term expiring at the Company’s 2029 annual meeting of stockholders.Director or officer change · Form 8-K
- Jun 22, 2026On June 17, 2026, stockholders of CytomX Therapeutics, Inc. (the “Company”) approved at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”) an amendment (the “2015 Plan Amendment”) to the Company’s Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”) and an amendment (the “ESPP …Director or officer change · Form 8-K
- Jun 3, 2026CytomX Therapeutics, Inc. (the “Company”) previously entered into that certain Collaboration and License Agreement, effective November 16, 2022 (as amended, the “Agreement”), with Regeneron Pharmaceuticals, Inc. (“Regeneron”), providing for the collaboration on the creation of conditionally-activated investigational …Material agreement entered · Form 8-K
- May 7, 2026CytomX Therapeutics Announces Q1 2026 Financial Results and Provides.Earnings release · press release
- Mar 19, 2026On March 17, 2026, CytomX Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the …Other event · Form 8-K
- Mar 16, 2026CytomX Therapeutics Announces 2025 Financial Results and Provides.Earnings release · press release
- Nov 6, 2025CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…